Cathie Wood goes biotech shopping, shells out $7.7 million | Official Website of Louis Velazquez, entrepreneur, finance guy and tech innovator

Cathie Wood isn’t backing off biotech any time soon.

The ARK Innovation ETF (ARKK) is killing it, too, surging 32% year-to-date, giving her the impetus to continue investing millions in biotech stocks.

That extends her months-long spree into shelling out millions in volatile genomics names. However, the moves are a lot less tactical and more thematic.

💵💰Don’t miss the move: Subscribe to TheStreet’s free daily newsletter💰💵

In a May interview with MarketWatch, Wood called health care “the most underappreciated beneficiary of AI.”

She also forecasted a broader rally in the coming months: “We believe the market…is going to broaden out and reward some of the companies that have lagged behind badly.”

This isn’t a pivot, but it’s Cathie’s thesis in motion.

Cathie Wood goes biotech bargain-hunting, splashing $7.7 million on gene-editing bets.

Image source&colon; Ratcliffe/Bloomberg via Getty Images

Cathie Wood bets big, stays bold, and plays the long game

Cathie Wood’s ARK Invest is more of an anomaly in active management.

The flagship ARKK ETF holds just 40 to 45 names, with its top 10 accounting for roughly 56 to 57% of assets.

To be fair, that’s a far cry from the diversified, benchmark-aware approach typically used by traditional managers.

More News:

Here’s a list of its thematic equity ETFs, six of which are actively managed, plus a few indices:

Cathie Wood’s Active equity Exchange-Traded Funds:

ARKK: ARK Innovation ETF
ARKG: Genomic Revolution ETF
ARKQ: Autonomous Tech & Robotics ETF
ARKW: Next Generation Internet ETF
ARKF: Fintech Innovation ETF
ARKX: Space Exploration & Innovation ETF

Index:

PRNT: The 3D Printing ETF
IZRL: ARK Israel Innovative Technology ETF

The portfolios effectively embrace high tracking error and volatility in pursuit of “disruptive innovation.”

Additionally, ARK discloses trades daily, offering transparency that’s typically rare in active positioning. Nevertheless, the payoff profile is pure boom-bust:

+152.8% in 2020
-23.4% in 2021
-67.0% in 2022
+67.6% in 2023
+32% year-to-date through August 31, 2025

ARK’s strategy involves riding out multi-year innovation cycles, with Morningstar pegging ARK’s firmwide assets under management at a whopping $30 billion as of early 2025.

Needless to say, Wood is laser-focused on genomics as a critical innovation pillar. For perspective, ARKG, her biotech-specific fund, zeroes in on DNA sequencing, CRISPR, targeted therapies, diagnostics, and bioinformatics.

Naturally, the risk is high, but so is the conviction.

Cathie Wood doubles down on biotech, trims Roku and DraftKings

Cathie Wood came out swinging after a long weekend, putting more money to work in her favorite corner of innovation in biotechnology.

The ARK Innovation ETF scooped up millions worth of gene-editing and sequencing stocks, while Wood lightened up bigger consumer tech names, including Roku and DraftKings.

Here were some of the notable additions and trims:

CRISPR Therapeutics: +$2.9 million (56,273 shares)
10X Genomics: +$2.9 million (215,278 shares)
Intellia Therapeutics: +$1.9 million (169,686 shares)
Roku: -$10 million (104,713 shares sold)
DraftKings: -$2.15M (44,861 shares sold across 3 ARK funds)

Crispr Therapeutics is synonymous with Cathie Wood and now ranks at number 10 across ARK’s combined portfolio, worth an eye-catching $428.7 million, with a portfolio weighting of 3.29%.

Her consistent backing shows a belief that gene editing is essentially on the cusp of commercial breakthroughs.

With 10X Genomics, Wood is basically buying the dip. ARK added $2.9 million as the stock cooled off, signaling confidence that TXG’s sequencing technology is critical for next-gen biotech research.

Intellia also saw steady buying. Though it’s down roughly 6% in the past month, ARK continues to add to its exposure, suggesting Wood views recent weakness as mostly temporary.

On the other side, Wood’s Roku sales show profit-taking after a 32% three-month surge, while DraftKings’ trims point to continued caution in the consumer internet niche.